Prospects for vaccine prevention of meningococcal infection
about
Anti-cytokine and anti-endotoxin therapies for meningococcal diseaseAnti-cytokine and anti-endotoxin therapies for meningococcal diseaseImportance of circulating antibodies in protection against meningococcal diseaseMeningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseaseNeisseria meningitidis recruits factor H using protein mimicry of host carbohydratesReview of meningococcal vaccines with updates on immunization in adultsMulticomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United StatesEpidemiological profile of meningococcal disease in the United StatesPopulation structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-20051H, 13C and 15N assignment of the C-terminal domain of GNA2132 from Neisseria meningitidisImmune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005.Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Meningococcal disease serogroup C.Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.Intranasal vaccines for protection against respiratory and systemic bacterial infections.A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlersThe changing epidemiology of meningococcal disease in North America 1945-2010.Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey. A multicenter prospective surveillance studyMeningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002.Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraComparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age.Meningococcal vaccines: a neglected topic in travel medicine?Optimizing protection against meningococcal disease.The epidemiology of meningococcal disease and the impact of vaccines.Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention.Epidemiology and meningococcal serogroup distribution in the United States.Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.New frontiers in meningococcal vaccines.Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).Designing a new antifungal glycoconjugate vaccine.Two cases of meningococcal purpura fulminans: the 'less is more' approach.Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.
P2860
Q24186999-B86CDDA5-50E2-451F-AF21-A0BC837A5B59Q24234359-4922C4FC-7729-472A-8710-93AC5A65FC54Q27023516-5D6FDDA2-F2F5-48B3-B1F0-0031D6BAB6B1Q27028161-B4BB77A1-8837-4B31-8BD9-CB7CC1C15FDEQ27653843-9AC3F4DC-C7D6-432D-AC1B-66AB877E96E2Q28828692-4C9ABFAB-D488-4021-913A-12C24DC4D471Q30235072-9D3F4EE8-5E90-429A-B599-99A023722797Q33648635-9977551B-3076-4FD0-BB9B-FBE3895BC726Q33729202-169979BD-D10B-4298-A494-F2C6B2BE2EC4Q33820835-852DC114-5F2E-4D82-8507-817042B61991Q34627685-8445EA55-B8AF-4424-B002-8BECF2F81C8DQ35069945-F2EC06BA-B0FB-40F2-BBC2-EBA9814CBCE2Q35783606-66CB2490-B1BC-4E66-8D2B-EB83C36016DBQ35832179-546DBE41-61EC-48C6-AB96-8EEA563E49F8Q36391874-D56A87F1-1D48-4289-A29C-56104C55F18EQ36434366-931B8FEB-BF4C-4DD5-9B7B-27D7EA724D61Q36781534-FEDB1D50-3922-447E-ADD0-3D54FF2F2911Q36791713-E30033E1-BD25-4837-A98D-2A2087E432E6Q36837156-1D8BB098-4BB6-43A8-8CA1-A548DB3D91BAQ36849830-296EF064-DDF9-43A8-8508-795377C186EFQ36849834-CB620956-6E99-4B0B-B29E-CD076D96A4EBQ36887966-1414B81D-6C82-4212-B1A6-61FCA66FEDDAQ37159647-98578B25-5DCC-44AE-BB84-0C025EC317A5Q37252405-2F043DC9-DB8C-47EE-BF69-EB772820FE0BQ37333542-EEB5DBEF-D0D3-4350-8D6D-8FB8D3AB5600Q37450825-5CA36A44-112F-46A4-9F81-E0B8A0FF7FBCQ37600163-34108F19-1E50-4459-9098-30B6C4CEFC5DQ37608305-69B55A63-36BF-41BF-9078-B61545F64ED1Q37678717-0EAB1475-0DBE-49DD-9EEF-8C810C3677B2Q37706585-D164295E-BCE0-4F6B-A244-CDF0783F3DDBQ37734624-886F1F43-1022-4A6F-8137-A483C618CC09Q37761235-DCB24F54-D908-4772-BB74-062E71F05D49Q37798011-07E49979-2B48-4780-A197-4FF081BB5307Q37878480-0EA83CDA-88DB-498E-9C35-3C74E1641689Q37909415-E1AFE187-B946-4B76-8356-1BF4936D54A0Q38028992-038D2B80-AEC5-4D1B-8DE8-39F35A27F8C8Q38066532-86D667B2-BFA4-4379-8CBE-833E3EEF6846Q38066728-D42C7503-BA42-4BFA-83A2-1F546C407CC3Q38074479-49DA8AC9-B3FF-4BDA-A0CB-DFF8B3740DE8Q38104685-B9280DCE-3B5A-4BB0-AEBA-EDDBF5BE59D9
P2860
Prospects for vaccine prevention of meningococcal infection
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prospects for vaccine prevention of meningococcal infection
@ast
Prospects for vaccine prevention of meningococcal infection
@en
Prospects for vaccine prevention of meningococcal infection
@nl
type
label
Prospects for vaccine prevention of meningococcal infection
@ast
Prospects for vaccine prevention of meningococcal infection
@en
Prospects for vaccine prevention of meningococcal infection
@nl
prefLabel
Prospects for vaccine prevention of meningococcal infection
@ast
Prospects for vaccine prevention of meningococcal infection
@en
Prospects for vaccine prevention of meningococcal infection
@nl
P2860
P1476
Prospects for vaccine prevention of meningococcal infection
@en
P2093
Lee H Harrison
P2860
P304
P356
10.1128/CMR.19.1.142-164.2006
P407
P577
2006-01-01T00:00:00Z